Type 2 & other diabetes

Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study

Diabetes Obes MetabPublished Prospective cohort study

Main finding · Increased residual gastric contentResult — go to the resultOdds ratio 2.52 95% CI 1.84–3.45

Authors' conclusion

GLP-1 RA therapy is a potent, independent driver of significant gastric retention in patients with T2DM, persisting despite standard fasting. Crucially, the presence of diabetic retinopathy or nephropathy identifies a "double-hit" high-risk phenotype, where pharmacological delay interacts with microvascular burden. These findings suggest that current fasting protocols may be insufficient for these patients, necessitating individualized preoperative assessment based on microvascular status and dosing timing.

Study context

Population
Inpatients with T2D aged 18–80 years, BMI <40 kg/m², without conditions affecting gastric motility, Endocrinology Department of Ningbo No.2 Hospital, April–December 2024; gastric US after standard overnight fast237 [60.8%] male
Participants
390 inpatients
Exposure
GLP-1 RA users vs non-users
  • GLP-1 RA usersn = 224
Outcome
Prevalence of increased residual gastric content (solid content or clear fluid volume >1.5 mL/kg)
Follow-up
After standard overnight fast
Methodological detailssingle-centre, propensity score matching, inverse probability of treatment weighting
  • Single-centre
  • Propensity score matching
  • Inverse probability of treatment weighting

Main finding

Increased residual gastric content

Odds ratio

2.52

95% CI 1.84–3.45

By group

GLP-1 RA usersvs Non-users
OR 2.52 (95% CI 1.84–3.45)

As reported in the abstract

Observational data: associations, not effects.

Further findings

Risk factors for increased residual gastric content

Diabetic retinopathy, OR
1.84 (95% CI 1.14-2.99)
Diabetic kidney disease, OR
1.67 (95% CI 1.17-2.39)
  • Independent risk factors

Days since last GLP-1 RA dose and increased residual gastric content (GLP-1 RA users)

aOR per additional day (95% CI 0.65-0.90); odds reduced by 23%
0.77

Original publication

Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study. Diabetes Obes Metab. Published 3 February 2026. doi:10.1111/dom.70537

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.